2 papers
q-bio.BM2024
Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights from Joint Modeling and Large-Scale Data Analysis
Benjamin K. Schneider, Sebastien Benzekry, Jonathan P. Mochel
Non-small cell lung cancer (NSCLC) is often intrinsically resistant to several first- and second-line therapeutics and can rapidly acquire further resistance after a patient begins…
q-bio.CB2024
Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
Benjamin Schneider, Sébastien Benzekry, Jonathan Mochel
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to the…